Vish Sridharan, MD
Vish Sridharan is a Research Analyst on the Health Care Sector Research Team at Janus Henderson Investors, a position he has held since 2022. In this role, he is focused on biotechnology companies. Before joining the firm, he completed an internship at Farallon Capital Management on the healthcare team investing in public and private biotechnology companies. He completed a residency in internal medicine at Massachusetts General Hospital while also serving as a consultant for Slate Path Capital, where he advised on science intensive opportunities. Additionally, Vish has worked with numerous biotechnology, capital management and pharmaceutical firms while earning multiple professional degrees and performing research at the Dana Farber Cancer Center and Brigham and Women’s Hospital.
Vish received a bachelor of science degree (Hons) in chemistry from University of North Carolina, graduating Phi Beta Kappa and an MBA from Harvard Business School. He also earned a doctor of medicine degree from the Harvard-MIT Program in Health Science and Technology, graduating with honours. He has 3 years of financial industry experience.
Global Perspectives: Why biotech could be embarking on a new decade of growth
A wave of innovative therapies is beginning to hit the market, transforming the prospects of the biotech firms behind the science.